The treatment of acute bacterial infections, which affect the skin and its structure should not be complicated. However, they turn out to be severe if there is an underlying disease, and surgery may be necessary. Nonetheless, according to Nabriva Therapeutics (NASDAQ:NBRV), SIVEXTRO is an ideal treatment for acute bacterial skin infections primarily caused by specific vulnerable Gram-positive microorganisms.
The company has since established a sales and marketing settlement with the subsidiaries of pharma giant Merck & Co., Inc. (NYSE:MRK). While the financial terms are still under wraps, the terms dictate that Nabriva will sell and distribute the oxazolidinone-class antibacterial in the United States and other particular territories.
The Transaction Is Aligned With Nabriva’s Corporate Strategy of Increasing Its Revenue
The treatment, which was approved in 2014 by the FDA targets pediatric patients 12 years of age as well as adults. It is packaged in 200 mg and is administered orally, once daily, or as an intravenous (IV) infusion for six days.
Being able to work with Merck is a significant milestone, according to CEO of Nabriva, Ted Schroeder. Merck has the exposure and expertise and innovation, which will help Nabriva push through its corporate strategy of increasing its revenue.
Merck has been in the pharmaceutical industry for more than 80years, driving its innovation in the development of novel medicines that combat infectious diseases. It has made such an incredible difference in the antibacterial marketplace, becoming one of the leading pharmaceutical companies globally.
Nabriva’s Engagement with Amplify Health
In the wake of the rising demand for advanced vaccines, Nabriva has also reached to Amplify Health. The organization will offer sales services for SIVEXTRO and XENLETA. Amplify has an in-depth experience of educating prescribers about the proper use of two antibiotics. Clinicians will also be taught the different attributes, which make the products optional treatment for patients.
Meanwhile, Merck has explained its position regarding the race for developing a COVID-19 vaccine. The company was conspicuously quiet but not anymore because it has entered into different deals to develop and manufacture different COVID-19 vaccines. According to the company’s President, Roger Perlmutter, the silence was deliberate.